Publications by authors named "Yan Naung Win"
Aims: Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized.
View Article and Find Full Text PDFArticle Synopsis
- * A meta-analysis involving 2,681 patients from various clinical trials found that while amodiaquine prolongs the QT interval, it does so less than chloroquine and piperaquine but more than lumefantrine and pyronaridine.
- * In patients aged 12 and older, amodiaquine was linked to a significant decrease in heart rate compared to other treatments, suggesting a greater risk of bradycardia compared to some alternative antimalarial medications.
Article Synopsis
- Electrocardiographic QT interval prolongation is a key risk marker for ventricular arrhythmia and is crucial in assessing the cardiotoxicity of antimalarial drugs.
- A systematic review and meta-analysis of data from 43 studies involving over 10,000 individuals aimed to understand how malaria and demographic factors affect the QT interval during treatment with antimalarials.
- The findings indicated that patients with uncomplicated falciparum malaria actually experienced shorter QT intervals compared to healthy individuals, suggesting that malaria itself may influence ECG readings and complicate interpretations of drug cardiotoxicity.
Background: Dihydroartemisinin-piperaquine is an effective and well tolerated artemisinin-based combination therapy that has been assessed extensively for the prevention and treatment of malaria. Piperaquine, similar to several structurally related antimalarials currently used, can prolong cardiac ventricular repolarisation duration and the electrocardiographic QT interval, leading to concerns about its proarrhythmic potential. We aimed to assess the risk of potentially lethal iatrogenic ventricular arrhythmias in individuals receiving dihydroartemisinin-piperaquine.
View Article and Find Full Text PDF